Article as featured in the Financieel Dagblad (Financial Times), 29 November 2024 (link)
Annogen announces successful identification of cell-specific promoters for Orchard Therapeutics’ preclinical gene therapy programs
Annogen today announced a research collaboration with Orchard Therapeutics, a global gene therapy leader, for the identification of immune cell-specific human promoters for use in certain pre-clinical hematopoietic stem cell (HSC) gene therapy programs.
